Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report
Authors:
- Alberto BongiovanniABAlberto Bongiovanni
- Nada RivaNRNada Riva
- Marianna RicciMRMarianna Ricci
- Laura MercataliLaura Mercatali
- Chiara LiveraniCLChiara Liverani
- Federico La MannaFMFederico La Manna
- Alessandro De VitaAlessandro De Vita
- Davide CavaliereDCDavide Cavaliere
- Federica PieriFPFederica Pieri
- Devil OboldiDODevil Oboldi
- Giorgio Maria VerdecchiaGVGiorgio Maria Verdecchia
- Dino AmadoriDADino Amadori
Open Access
- 22 December 2015
- journal article
- case report
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-6
Abstract
Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. The prognosis for this tumor is poor, with survival rates among the lowest of all soft tissue sarcomas. Surgery is the best approach for localized disease. The principal role of chemotherapy is prevalently in the treatment of metastatic disease. Trabectedin, a promising new DNA-damaging agent with a mechanism of action that differs from that of traditional alkylating agents, has been approved in Europe for the treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, We report the case of a 53-year-old woman with metastatic well differentiated uterine leiomyosarcoma refractory to multiple treatments who underwent 22 cycles of trabectedin over 30 months, obtaining a partial response according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria, with good tolerability, and maintaining the response for 10 months after trebectedin withdrawal. This very prolonged response, which persisted after drug discontinuation, suggests that trabectedin exerts an oncostatic effect rather than the cytotoxic one produced by other chemotherapeutic agents. Our experience also raises the question of the best way to evaluate trabectedin efficacy.Keywords
This publication has 36 references indexed in Scilit:
- Leiomyosarcoma: A Rare Tumor of the ThyroidEndocrine Pathology, 2013
- Rapid Growing Superficial Cutaneous Leiomyosarcoma of the FaceAnnals of Dermatology, 2013
- Primary Endobronchial Leiomyosarcoma of the Lung: Clinical, Gross and Microscopic Findings of Two CasesJournal of Clinical Imaging Science, 2012
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue SarcomasJournal of Clinical Oncology, 2012
- Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centersGynecologic Oncology, 2011
- Systemic therapy for advanced soft tissue sarcomasCancer, 2011
- Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular TestingPLOS ONE, 2011
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different SchedulesJournal of Clinical Oncology, 2009
- Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II studyGynecologic Oncology, 2008
- Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)European Journal of Cancer, 2008